Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
9 lessons
8mThe loudest peptide stories are moving at different speeds. PCAC recommendations await FDA action, oral GLP-1 access is real, and the next obesity programs still have filing or review milestones ahead.
8mRetatrutide is still the loudest metabolic signal in the room. The people who get the best result are the ones who track body composition, not just pounds lost.
9mRetatrutide keeps stacking strong data, and the latest trial update sharpens the path toward an FDA submission. The bigger story is not just weight loss. It is how the triple-agonist profile may change what obesity medicine expects from a next-wave therapy.
10mOrthopaedics is paying closer attention to peptides because the field keeps running into the same problem: recovery is biology, but biology still needs evidence before it becomes a protocol.
9mRetatrutide's weight-loss signal is now strong enough that people are comparing it with surgery. That comparison is useful, but only if you understand what the numbers do and do not mean.
7mA 2025 Biomolecules review highlights the hardest GLP-1 question: what happens after the weight comes off? Maintenance needs a plan before the final dose.
7mEDS changes the safety conversation around peptides. GHK-Cu, BPC-157, and TB-500 are discussed for tissue support, but EDS plus cardiac history should stay clinician-led.
9mMOTS-C activates AMPK through mitochondrial signaling. NAD+ feeds the cellular energy substrate. Together, they hit the same system from two different angles — and the results are additive.
9mCJC-1295 with DAC lasts ~6–8 days (weekly pins). Without DAC (Mod GRF 1-29) lasts ~30 minutes and needs co-injection with Ipamorelin. Comparison table, doses, and which to pick.
Also available at /blog for legacy links.